Share

June 2013; 3 (3) Drugs and Devices

Teriflunomide

Jiwon Oh, Paul W. O’Connor
First published June 10, 2013, DOI: https://doi.org/10.1212/CPJ.0b013e318296f299
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
645

Share

Article Information

vol. 3 no. 3 254-260
DOI: 
https://doi.org/10.1212/CPJ.0b013e318296f299
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published June 10, 2013.
Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Jiwon Oh, MD, FRCPC and
    2. Paul W. O’Connor, MD, MSc, FRCPC
  1. Jiwon Oh, MD, FRCPC and
    2. Scientific Advisory Boards:

    1. (1) EMD-Serono, Scientific advisory board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Teva Neurosciences, Educational travel support

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Multiple Sclerosis Society of Canada Transitional Career Development Award

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Paul W. O’Connor, MD, MSc, FRCPC
    3. Scientific Advisory Boards:

    1. Novartis Fingolimod Steering Committee--member--2007-present, Teriflunomide Steering Committee ( sanofi aventis)--chairman--2006-present, Bayer BEYOND study steering committee--chairman--2007-2009, BRAVO (laquinimod) study DMC--chairman--2007-present, Genentech advisory board--member, Roche advisory board, Receptos advisory board, Actelion advisory board

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Funding for travel or speaker honoraria: 1 Biogen Idec-ECTRIMS meeting Dusseldorf--2009--presentations of data from two studies, 2 Teva--Meeting in London--advise and present data on safety of MS drugs--2009, 3 Advisory board meeting in Montreal 2010

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen Idec consultant 2007-2012, Actelion consultant 2010, Bayer Consultant 2007-2009, EMD Serono Consultant 2009-11, Teva Consultant 2007-2012, Genentech Consultant 2007-2008, Sanofi Genzyme Consultant 2002-2012, Novartis Consultatn 2005-2012, Warburg Pincus Consultant 2009

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1 Bayer--study grant support for BEYOND study--2006-82 Novartis--study grant support for FREEDOMS, TRANSFORMS and INFORMS study--2006-2012, 3 BIOMS--study grant support 2006-9, 4 Sanofi Aventis-grant supprot for TEMSO, phase 2 , CIS and nerispirdine studies, 5 ROCHE; grant supprot for phase 2 OCRELIZUMAB study, 6 Biogen Idec: grant support for ASCEND and JEMS study, 7 Roche grant support for OPERA and ORATORIO studies

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Scientific and Clinical Advisor to to the MS Society of Canada. 2008-2009 (ongoing)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology (JO), Johns Hopkins University, Baltimore, MD; and Division of Neurology, Department of Medicine (JO, PWO), St. Michael's Hospital, University of Toronto, Toronto, Canada.
  1. Correspondence to:
    oconnorp{at}smh.ca
View Full Text

Article usage

Article usage: May 2013 to July 2022

AbstractFullPdfSource
May 2013031Highwire
Jun 20134593075Highwire
Jul 2013302428Highwire
Aug 2013233526Highwire
Sep 201310208Highwire
Oct 20137921Highwire
Nov 20139525Highwire
Dec 20137443Highwire
Jan 20146743Highwire
Feb 201455510Highwire
Mar 20144021Highwire
Apr 20146205Highwire
May 20143413Highwire
Jun 20144011Highwire
Jul 20144411Highwire
Aug 20142504Highwire
Sep 20142704Highwire
Oct 20144013Highwire
Nov 20142715Highwire
Dec 20142700Highwire
Jan 20154001Highwire
Jan 20150149pmc
Feb 20152704Highwire
Feb 20150123pmc
Mar 20153701Highwire
Mar 201503610pmc
Apr 20153402Highwire
Apr 2015096pmc
May 20152801Highwire
May 20150126pmc
Jun 20152011Highwire
Jun 20150179pmc
Jul 20151802Highwire
Jul 20150231pmc
Aug 20152611Highwire
Aug 20150168pmc
Sep 20153522Highwire
Sep 20150186pmc
Oct 20151900Highwire
Oct 20150239pmc
Nov 20152301Highwire
Nov 201501610pmc
Dec 20152510Highwire
Dec 20150226pmc
Jan 20162903Highwire
Jan 20160135pmc
Feb 20163001Highwire
Feb 20160174pmc
Mar 2016800Highwire
Mar 20160123pmc
Apr 20161800Highwire
Apr 2016082pmc
May 20162110Highwire
May 2016083pmc
Jun 20161702Highwire
Jun 20160187pmc
Jul 20161801Highwire
Jul 2016073pmc
Aug 20161601Highwire
Aug 20160101pmc
Sep 20162100Highwire
Sep 20160122pmc
Oct 20162811Highwire
Oct 20160172pmc
Nov 20163510Highwire
Nov 20160375pmc
Dec 20161200Highwire
Dec 2016082pmc
Jan 20173201Highwire
Jan 20170144pmc
Feb 20171900Highwire
Feb 20170173pmc
Mar 20171300Highwire
Mar 20170120pmc
Apr 20171500Highwire
Apr 201731314pmc
May 20171600Highwire
May 201742326pmc
Jun 20171402Highwire
Jun 201741518pmc
Jul 2017602Highwire
Jul 201771921pmc
Aug 2017500Highwire
Aug 201711515pmc
Sep 2017500Highwire
Sep 201752830pmc
Oct 2017401Highwire
Oct 201752119pmc
Nov 2017711Highwire
Nov 201721213pmc
Dec 2017710Highwire
Jan 20181822Highwire
Feb 20181600Highwire
Mar 20181111Highwire
Apr 2018911Highwire
Apr 201852028pmc
May 20181211Highwire
Jun 20181500Highwire
Jun 201861720pmc
Jul 20183521Highwire
Aug 20182510Highwire
Aug 201875166pmc
Sep 2018801Highwire
Oct 20182000Highwire
Nov 20181311Highwire
Dec 20181510Highwire
Jan 20191400Highwire
Feb 2019900Highwire
Mar 2019900Highwire
Apr 20191600Highwire
May 20191100Highwire
Jun 2019900Highwire
Jul 2019800Highwire
Aug 20191311Highwire
Sep 20192100Highwire
Oct 20191011Highwire
Nov 20191401Highwire
Dec 20191900Highwire
Jan 20201000Highwire
Feb 20201900Highwire
Mar 20201310Highwire
Apr 20202200Highwire
May 20201401Highwire
Jun 20201001Highwire
Jul 20201512Highwire
Aug 20203801Highwire
Sep 2020900Highwire
Oct 20203510Highwire
Nov 20201300Highwire
Dec 20201810Highwire
Jan 20211300Highwire
Feb 20211300Highwire
Mar 20211200Highwire
Apr 20212000Highwire
May 2021910Highwire
Jun 20212611Highwire
Jul 20213202Highwire
Aug 20212900Highwire
Sep 20213100Highwire
Oct 20213410Highwire
Nov 20212610Highwire
Dec 20213401Highwire
Jan 20224512Highwire
Feb 20224100Highwire
Mar 20222710Highwire
Apr 20223502Highwire
May 20224211Highwire
Jun 20223010Highwire
Jul 20222302Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me